5:31 AM
 | 
Apr 12, 2018
 |  BC Extra  |  Politics & Policy

FDA streamlining cancer diagnostics development

Editor's Note: This article was updated on Apr 12, 2018 at 8:01 AM PDT

FDA Commissioner Scott Gottlieb Thursday announced new policies that are intended to encourage development of next-generation sequencing (NGS) technology for cancer diagnostics.

In a speech to the Community Oncology Alliance, Gottlieb presented the new guidance documents as part of broader policies that are intended to reduce the cost and improve the quality of cancer drug development. He emphasized the need to reduce drug costs and argued that lower development costs will help achieve this goal.

“Rising co-pays and co-insurance are pushing far too many patients into a financial no-man’s land where sometimes they must literally choose between exhausting their bank accounts,...

Read the full 483 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >